Managing Symptom Clusters in Patients on Hemodialysis With CKD-aP
Kelly Chenlei Li, MBBS, FRACP
Paul Bennett, RN, MHSM, PhD, FISN
Thilo Krüger, MD, PhD
Noninvasive Tests for Clinically Significant Fibrosis: That's The Hepatologist's Job, Right?
Naim Alkhouri, MD, FAASLD, DABOM
Endocrinologists and PCPs: The Frontline Defense Against Cirrhosis in Patients with Type 2 Diabetes
Jeff McIntyre
Robert H. Eckel, MD, FAHA, FACC, FNLA
Tessa Janovsky, PA-C
I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis
More Screening Recommendations? These Could Save Your Patient's Life
Treating Patients With T2D and MASLD: Is the Tide Changing?
M3: Managing the Cardiometabolic Risk in MASH
Strategic Excellence: Mastering the Expanding ATTR-CM Therapeutic Landscape in Pharmacy Practice
Hongya Chen, PharmD
Jennifer Day, PharmD
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA
Overcoming Clinical Inertia in Hyperkalemia Management
Peter Rossing, DMSc, MD
Michael Böhm, MD, FESC
Luca De Nicola, MD, PhD
Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
Jay Reddy, MD, FASN
Carlos Narváez Mejía, MD
It’s All About Patient Identification
Renuka Jain, MD
Challenging TAVR Cases
Steven Yakubov, MD, MSCAI, FACC
New TAVR Data – New TAVR Talk Track
Hemal Gada, MD
The Changing TAVR Landscape
Pam R. Taub, MD, FACC, FASPC
Roxana Mehran, MD
Ashish Aneja, MD
Deepak Talreja, MD, FACC
Anene Ukaigwe, MD
Elana Koss, MD
Beyond Longevity: Discussing TAVR Durability for Women & Patients With Small Annuli
Contemporary TAVR Outcomes in Patients with Small Aortic Annulus: A Review of Recent Trial Data